You Lu
Principal Investigator · Study Principal Investigator · West China Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
29
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
2 more share only the name and are not shown
Trial papers
1098
PubMed author-name match
Trials
Studies that name You Lu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:45 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07258147 · Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver MetastasesSichuan University · not yet recruiting · Lung Cancer (SCLC) · principal investigator
- Ph2NCT06877299 · Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung CancerSichuan University · recruiting · Lung Cancer, Non-small Cell Lung Cancer · principal investigator
- Ph2NCT06610734 · Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)Sichuan University · recruiting · Small Cell Lung Cancer Extensive Stage · principal investigator
- Ph1NCT06431685 · Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung CancerSichuan University · recruiting · NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor · principal investigator
- Ph1NCT06349837 · Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky TumorsSichuan University · recruiting · Solid Tumor · principal investigator
- Ph1NCT06348797 · Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLCSichuan University · recruiting · Small Cell Lung Cancer Extensive Stage · principal investigator
- Ph1/Ph2NCT06217757 · Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCSichuan University · recruiting · Lung Cancer, Extensive-stage Small-cell Lung Cancer · principal investigator
- Ph1/Ph2NCT06195189 · Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/IISichuan University · recruiting · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT06121505 · Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung CancerSichuan University · recruiting · Lung Squamous Cell Carcinoma · principal investigator
- Ph1NCT05768321 · Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C MutationGenEros Biopharma Hangzhou Ltd · unknown · Advanced Solid Tumors · principal investigator
- Ph2NCT05765825 · Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLCSichuan University · active not recruiting · Extensive-stage Small-cell Lung Cancer · study chair
- Ph1NCT05615142 · Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.Sichuan University · active not recruiting · NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy · principal investigator
- Ph1NCT05378178 · A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid TumorsJiangsu Hansoh Pharmaceutical Co., Ltd. · unknown · Advanced Solid Tumor · principal investigator
- Ph2NCT05215951 · Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLCAstraZeneca · terminated · Lung Cancer · principal investigator
- Ph2NCT05186506 · A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung CancerSichuan University · not yet recruiting · ALK Fusion Protein Expression, Adjuvant Therapy, Non-Small Cell Lung Cancer · study chair
- Ph2NCT05092412 · Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLCYou Lu · active not recruiting · Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab · study chair
- Ph2NCT04878107 · SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and ChemotherapyWuhan University · unknown · Non-Small Cell Lung Cancer · principal investigator
- Ph1NCT04421352 · Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC PatientsCStone Pharmaceuticals · completed · Relapsed Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT04400188 · A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung CancerJiangsu HengRui Medicine Co., Ltd. · completed · Small Cell Lung Cancer · study chair
- Ph1NCT04012619 · Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung CancerSichuan University · completed · Non-squamous Non-small-cell Lung Cancer, Anlotinib · principal investigator
- Ph1NCT03812549 · Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC PatientsSichuan University · completed · Stage IV NSCLC · principal investigator
- N/ANCT03559803 · A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix CancerSichuan University · unknown · Cervical Cancer · principal investigator
- N/ANCT03373955 · A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC PatientsSichuan University · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph1NCT02793856 · PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung CancerSichuan University · completed · Metastatic Non-small Cell Lung Cancer · principal investigator
- Ph2NCT02726568 · High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain MetastasesBetta Pharmaceuticals Co., Ltd. · unknown · Non-small Cell Lung Cancer, Brain Metastases · principal investigator
- Ph4NCT02299765 · Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLCSichuan University · terminated · Non-small Cell Lung Cancer Metastatic, EGFR Activating Mutation · study director
- Ph1NCT02004548 · Phase I Clinical Study of Metatinib Tromethamine TabletJiangsu Simcere Pharmaceutical Co., Ltd. · completed · Advanced or Metastatic Solid Tumors · principal investigator
- Ph2NCT01714908 · Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21Jinming Yu · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT01516983 · Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR MutationBetta Pharmaceuticals Co., Ltd. · completed · Non-small Cell Lung Cancer, Brain Metastases · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:45 UTC. The ranking covers the 200 most relevant of 1098 PubMed records, and a shared surname and initials can bring in a namesake. All 1098 on PubMed
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.Lancet · 20202,489 citationsRCR 131.1
- 2,116 citationsRCR 82.3
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.Lancet Oncol · 20211,003 citationsRCR 54.5
- 832 citationsRCR 35.3
- 508 citationsRCR 27.0
- 493 citationsRCR 19.9
- 363 citationsRCR 20.1
- 356 citationsRCR 18.6
- 342 citationsRCR 12.0
- 306 citationsRCR 18.8